Farma

BioBull
07.10.2020 kl 11:04 9581

BerGenBio’s Bemcentinib bør kjøpes før det er for sent for Merck og aksjonærene i BGBIO. Markedspotensiale for synergieffekten av Keytruda + Bemcentinib vil være enorm.
Å betale 25Mrd USD for BGBIO er småpenger...
Nå koster BGBIO 250 mill USD...
30 NOK x 10 = 300 NOK pr aksje - Do The Math !


Can Merck’s Keytruda Be Worth $200 Billion By 2025?
ShareProvide Feedback
#1A. Merck's Keytruda added about $10 billion revenue in last 4 years

Keytruda added $9.7 billion incremental sales over the last 4 years. Its sales grew from $1.4 billion in 2016 to $11.0 billion in 2019, led by approval in multiple indications.

Roughly $7 billion of Keytruda's sales come from lung cancer, while the rest, about $4 billion, comes from other indications ~ cervical, renal, gastric, Hodgkin's lymphoma, skin, and head & neck cancer.

Our dashboard Keytruda Sales vs Indications Timeline shows its approvals by year, and how approvals map into sales increase.

#1B. Keytruda Could Add Another $22 Billion Revenue By 2025 With Success On 2 Fronts

(i) Establishing leadership position in indications it has already entered, including lung, cervical, renal, gastric, Hodgkin's lymphoma, skin, and head and neck cancer, collectively worth more than $35 billion

(ii) Entering + establishing leadership positions in indications currently in trial, including breast, colorectal, ovarian, and prostate cancer, worth over $30 billion
Redigert 21.01.2021 kl 08:40

Rapportér innlegg

Vennligst skriv inn kommentar på hva du mener er upassende og trykk send. Dersom kommentar ikke er nødvendig, vennligst trykk send direkte.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.